Cure My Disease

Don't miss your cure!

 Log in / Sign up

Massive MS registry aims to decode why some patients worsen faster than others

NCT ID NCT03603457

Knowledge-focused Sponsor: EDMUS Foundation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time

Summary

This observational study follows thousands of people with multiple sclerosis (MS) over many years to identify factors that predict how the disease will progress. Researchers collect detailed clinical data, MRI scans, and quality-of-life questionnaires from participants treated at specialized MS centers in France. The goal is to build personalized prognostic tools that help doctors decide when to start or change treatments.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could lead to better tools for predicting how multiple sclerosis will progress in individual patients, helping doctors tailor treatments earlier.
What could go wrong
This is an observational study, not a treatment trial, so it cannot prove cause and effect. The findings may take years to translate into practical tools.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

2,842 people

The number who actually took part.

Started

Jul 2018

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

All MS patients from MS Clinical Reference Centre (CRC SEP).

Ages

15 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of multiple sclerosis according to the most recent criteria at entry into the HD cohort * Followed in one MS Clinical Reference Centre (CRC SEP) * Newly diagnosed after the study start or * If MS onset occurred before study start, regular follow-up in a CRC SEP * Irreversible disability ≤ 7.0 (permanent use of a wheelchair) on EDSS at inclusion in the study Non-inclusion Criteria: * Inability to answer questionnaires * Pregnant women at the time of inclusion

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple sclerosis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple sclerosis

Contacts and locations

Locations

  • CHI de Poissy-Saint-Germain-en-Laye

    Poissy, France

  • CHU Pitié-Salpétrière

    Paris, France

  • CHU Saint-Antoine

    Paris, France

  • CHU de Besançon

    Besançon, France

  • CHU de Bordeaux

    Bordeaux, France

  • CHU de Caen

    Caen, France

  • CHU de Clermont-Ferrand

    Clermont-Ferrand, France

  • CHU de Créteil

    Créteil, France

  • CHU de Dijon

    Dijon, France

  • CHU de Fort-de-France

    Fort-de-France, Martinique

  • CHU de Grenoble

    Grenoble, France

  • CHU de Lille

    Lille, France

  • CHU de Limoges

    Limoges, France

  • CHU de Lyon

    Lyon, France

  • CHU de Montpellier

    Montpellier, France

  • CHU de Nancy

    Nancy, France

  • CHU de Nantes

    Nantes, France

  • CHU de Nice

    Nice, France

  • CHU de Nîmes

    Nîmes, France

  • CHU de Poitiers

    Poitiers, France

  • CHU de Rennes

    Rennes, France

  • CHU de Strasbourg

    Strasbourg, France

  • CHU de Toulouse

    Toulouse, France

  • CHU de Tours

    Tours, France

  • Fondation Rothschild

    Paris, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.